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T h o u s a n d s o f A m e r i c a n s e a c h year s u f f e r s e r i o u s d a m a g e t o t h e i r d e l i -
c a t e c o r n e a s . A B U S M r e s e a r c h t e a m Is w o r k i n g t o d e v e l o p a r a d i c a l l y 
d i f f e r e n t a r t i f i c i a l c o r n e a t h a t m a y o v e r c o m e c o m m o n p r o b l e m s a s s o c i -
a t e d w i t h e x i s t i n g d e v i c e s . S e e s t o r y p a g e 3. 
Gennaro Carpinito, M.D., center, and Christine T. Carr, R.N., administer autolymphocyte ther-
apy to patient. The therapy is done on an outpatient basis. (Photo by Gustav Freedman) 
Early experience with 'customized' 
cancer therapy proves promising 
Researchers unravel 
molecular structure 
of key protein in 
cholesterol delivery 
A team of researchers in the Card io-
vascular Institute of Boston Univer-
sity Schoo l of Medic ine has suc-
c e e d e d in unravel ing the genet ic 
code , and thereby the st ructure, of 
an extraordinar i ly long protein mol -
ecule that is responsible tor the 
major i ty of work in t ranspor t ing cho-
lesterol f rom the b loods t ream to cells 
whe re it can be used . 
Scient ists have been work ing on 
the amino acid sequence of this pro-
te in, known as apol ipoprote in B 
(apoB) , tor the past 25 years, but 
had only s u c c e e d e d in ident i fy ing a 
str ing of 100 or so of its amino acid 
bui ld ing b locks. In the last 18 
months, a team headed by Vassil is 
Zann is , Ph.D. , an associate pro-
fessor of medic ine and di rector of 
the Sect ion of Molecular Genet ics at 
B U S M , has succeeded in sequenc-
ing the ent i re 4 ,560 amino acids that 
make up a p o B by us ing recombinant 
DNA techn iques and computer ana l -
yses . 
ApoB 's s igni f icance lies in its role 
as a t ranspor ter of the cholesterol 
that c i rculates in the b loods t ream. 
Th is cholesterol is obta ined largely 
f rom food c o n s u m e d ; some also is 
synthes ized by cel ls. Cel ls use cho-
lesterol for such purposes as bui ld-
ing membranes and , in some cases , 
hormones . 
The movement of cholesterol f rom 
continued on page 5 
A Boston Universi ty School of Med i -
cine group has deve loped a new 
cancer therapy in which the pat ient 's 
own immune cells are temporar i ly 
removed from the body, i m m u n i z e d 
to the cancer , and then in jected 
back into the patient. 
Early exper ience wi th this "cus-
t o m i z e d " type of therapy, cal led 
au to lymphocy te therapy, shows that 
it can be done on an outpat ient 
basis, has min imal side ef fects, and, 
most crucial ly, appears to prolong 
the lives of at least some of the c a n -
cer pat ients t reated. 
Au to lymphocy te therapy was 
deve loped by Michael E. Osband , 
M.D., an associate professor of 
pediatr ics at B U S M and director of 
the School 's Cl inical Immunotherapy 
Program, and col leagues Gennaro 
Garpini to, M.D., cl inical d i rector of 
the p rogram, and Robert J . Krane, 
M.D., professor and cha i rman of the 
B U S M Depar tment of Urology and 
chief of urology at the University 
Hospital . 
continued on page 2 
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Cancer therapy... 
continued from page 1 
T h e basic goal of the f irst studies 
done wi th au to lymphocy te therapy in 
1982 and 1983 was to establ ish 
whe ther it is feasible ..nd sate, not 
whe ther it works , said O s b a n d . Nev-
er theless, even though most of the 
f irst pat ients t reated had a par t icu-
larly lethal fo rm of cancer , metastat ic 
kidney d isease, a signi f icant number 
did much better than wou ld normal ly 
be expec ted . 
"Stud ies tor the past 50 years 
have shown that pat ients w i th metas-
tatic kidney cancer have a very poor 
p rognos is , " said O s b a n d . "On aver-
age, about halt are expec ted to die 
wi th in six mon ths . " Yet the research-
ers repor ted that, of 16 pat ients w h o 
l ived long enough tor the therapy to 
take effect, f ive exper ienced sub-
stantial shr inkage of their tumors . In 
tour other pat ients, the cancer 
s topped growing tor long per iods of 
t ime. 
"One patient has l ived more than 
th ree years to l lowing t reatment , in 
another case about two years, and 
in a th i rd about 18 months , " said the 
invest igator, who also d i rects 
B U S M ' s Laboratory of Cel lular 
Immuno logy and is head of B U S M ' s 
and Boston City Hospital 's Division 
of Pediatr ic Hemato logy-Onco logy . 
The researchers s ince have begun 
t reat ing a second g roup of pat ients, 
and several of t h e m also have expe-
r ienced reduct ions in tumor s ize. 
Au to lymphocy te therapy Is based 
on the theory that the cancer 
sp reads in some pat ients b e c a u s e 
the body 's immune sys tem does not 
at tack the tumors et tect ively. This 
may be due to prob lems wi th cer ta in 
kinds of wh i te b lood cells cal led T-
lymphocy tes , or T -ce l l s -so -ca l l ed 
b e c a u s e such cells reach matur i ty in 
the thymus g land. Cer ta in t ypes of 
T-cel ls, such as helper T-cel ls or 
killer T-cel ls, can bolster the body 's 
de fenses against tumors , O s b a n d 
sa id . But another g roup of T-
c e l l s - t h e suppressor T - c e l l s - m a y 
Michael E. Osband, M.D., developed the new 
cancer therapy, which appears to prolong the 
lives of some patients. (Photo by Bradford F. 
Herzog) 
somet imes undermine these de fenses . 
The normal role of suppressor cells 
is to inhibit immune responses, 
expla ined O s b a n d , and it is likely these 
cells are s imply car ry ing out that t radi-
t ional mission in some cancer pat ients. 
"What may happen is that the immune 
sys tem tails to recogn ize the tumor as 
fo re ign , " he said, "so there is no 
immune response, or it the body does 
init iate react ion in the immune sys tem, 
the suppressor cells cut oft any bud-
d ing response . " 
One piece of ev idence suppor t ing 
this theory is the tact that the number 
of suppressor T-cells is inc reased in 
many cancer pat ients. The aim of the 
B U S M group 's therapy is both to help 
the immune sys tem respond to the 
tumor, whi le at the same t ime reduce 
the act ivi ty of the suppressor cel ls. 
The process beg ins wi th the removal 
f rom the b lood of a smal l percentage of 
the body 's whi te cel ls. T h e B U S M 
group st imulates this f irst g roup of 
patient cells to act as a kind of cus tom-
ized factory, p roduc ing , tor that par t icu-
lar patient, a group of immune-sys tem 
chemica ls cal led mediators. A m o n g 
t h e m are such wel l -known mediators as 
interferon, inter leukin 1 and interleukin 
2, w h o s e roles include act ivat ing 
immune-sys tem cells like the helper T-
cells. 
"We th ink one important advan-
tage of our approach is that we ' re 
us ing mediators p roduced by the 
pat ient 's own cells, instead of inject-
ing a version of interleukin 2 or s o m e 
other mediator that was c reated 
th rough genet ic eng ineer ing , " sa id 
O s b a n d . "That makes it a more spe -
cific and potential ly less toxic regi -
m e n . " 
Wi th the patient 's own mix of 
mediators in hand, the group then 
draws more b lood from the pat ient 
and creates a lymphocyte cu l ture 
that contains the patient's mediators , 
an extract made from the pat ient 's 
tumor , and the pat ient 's own s e r u m , 
the l iquid port ion of the b lood wi th 
its red and whi te cells removed. 
Prior to every t reatment, a new 
group of whi te cells is removed f rom 
the patient and incubated in such a 
cul ture. Before the incubat ion star ts, 
however, the invest igators f irst e l imi -
nate as many suppressor T-cells as 
possible f rom the col lected whi te 
cel ls, a task readily car r ied out us ing 
exist ing b iochemical techn iques that 
they have deve loped. 
"In e l iminat ing most of the 
suppressor cel ls, we th ink we' re per-
mit t ing the other T-cel ls to be more 
readi ly ac t iva ted, " said Gennaro 
Carpin i to, M.D., w h o also is an 
assistant professor of uro logy at 
B U S M . 
After the pat ient 's whi te cells have 
been incubated tor th ree days, they 
are re in jected into the patient. The 
B U S M group also puts pat ients on a 
widely used d rug cal led c imet id ine. 
The d rug , usual ly employed to treat 
b leed ing ulcers, works by b lock ing 
suppressor cel ls, said Carpin i to. It is 
inc luded in th is therapy to fur ther 
boost the immune sys tem's abil i ty to 
at tack tumors by decreas ing 
suppressor cell act ivi ty. 
A l though the B U S M group does 
not know exact ly how the re in jected 
whi te cells and the c imet id ine work, 
they suspect that the combinat ion 
p roduces a t rue, long- last ing change 
in the pat ient 's immune sys tem. "On 
average, we ' re see ing a response 
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BUSM researchers strive to develop 
radically different artificial cornea 
roughly six months fo l lowing treat-
ment , " sa id Carpin i to . That f ind ing 
suggests that the t reated lympho-
cytes are themse lves not dest roy ing 
the tumor , but work by educa t ing 
other parts of the pat ient 's immune 
sys tem. The result Is an immune 
sys tem fully mob i l i zed to at tack the 
tumor . 
Drawing on their ear ly exper ience 
wi th the therapy, the B U S M invest i -
gators made some changes w h e n 
they began t reat ing their second 
g roup of pat ients last spr ing . For 
example , they are t ry ing to destroy 
still more suppressor cells before 
re in ject ing the whi te cel ls. 
T h e current cl inical trial wi l l end 
ear ly this year, w i th about 40 
pat ients having been t reated. T h e 
major i ty of t hose enrol led have been 
kidney cancer pat ients, a l though 
some wil l have cancer of the co lon 
or pancreas or wi l l have been been 
at t l ic ted by a v i rulent fo rm of sk in 
cancer cal led mal ignant me lanoma. 
Whi le it is too early in the second 
phase tor clear cut resul ts to have 
e m e r g e d , O s b a n d said that some of 
the pat ients t reated have s h o w n 
highly encourag ing responses . 
Meanwhi le , the B U S M team is 
ana lyz ing b lood samples f rom 
pat ients, in the hopes of shedd ing 
l ight on one of the key quest ions 
about the therapy: why s o m e 
pat ients respond whi le o thers do not. 
"By l imit ing au to lymphocy te ther-
apy to those pat ients in w h o m It is 
likely to work , " he sa id , "we might 
get a response rate of 80 or 90 per-
cent . " 
"Richard P. Anthony 
S u g g e s t e d F u r t h e r R e a d i n g s 
1. Carpinito, G.A. et al: Successful adoptive 
immunctlierapy of cancer using in vitro 
immunized autclcgus lymphocytes and 
cimetidine. Surg Forum 37: 419, 1986. 
2. Cavagnarc, J. and Osband, M.E.: Suc-
cessful in vitro primary immunization of 
human peripheral blood mononuclear cells. 
BioTechniques I: 30, 1983. 
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Thousands of Amer icans each year suf-
fer ser ious d a m a g e to their corneas , 
the th in , t ransparent outer coat ing of 
the eye that is vu lnerable to cer ta in dis-
eases and such t raumas as chemica l 
burns. 
There now are two basic t reatment 
al ternat ives tor pat ients w i th corneas 
that have been severely d a m a g e d : a 
corneal t ransplant , or implantat ion of an 
artlt icial cornea. Both al ternat ives have 
advantages and d isadvantages, accord -
ing to Vickery E. Tr inkaus-Randal l , 
Ph.D. , a research assistant professor of 
oph tha lmo logy and b iochemist ry at 
Boston Universi ty Schoo l of Medic ine. 
A l though a t ransp lanted co rnea can 
ot ter a long per iod of res tored v is ion, 
the graf ts of ten become c loudy and 
immunolog ic reject ion occurs . Another 
prob lem assoc ia ted wi th t ransplants, 
however, is that there are s imply not 
enough donated eyes avai lable. New 
corneas are be ing t ransplanted in Mas-
sachuset ts at the rate of about 562 a 
year, but the rate wou ld be much 
higher it more donated eyes were avai l-
able, exp la ined Tr inkaus-Randal l . 
"Condi t ions that af fect the co rnea 
severely enough to require corneal 
t ransplantat ion include corneal u lcera-
t ion, v i rus, bacter ia , fungi , keratoconus 
and cer ta in dyst rophic corneal d is-
e a s e s , " sa id Tr inkaus-Randal l . The cor-
nea also is vu lnerable to t rauma, she 
noted, w i th thermal and chemica l burns 
being two of the most c o m m o n sourc-
es. 
As tor arti t icial corneas, or kera-
topros theses, the main prob lem has 
been extrusion. " B e c a u s e there is no 
'heal ing, ' surgical manipulat ions must 
be emp loyed to secure the prosthes is , " 
exp la ined the invest igator. "Despi te the 
surgical manipulat ions, these devices 
have tai led because of necrosis of the 
adjacent t issue, in f lammat ion and 
epithel ial izat lon of the anter ior c h a m -
ber, whe re the epithel ial cells migrate 
d o w n and under the prosthesis and 
prol i terat ion occurs , caus ing extrusion 
of the dev ice . " Th is and other prob-
lems assoc ia ted wi th artit icial cor-
neas have prevented t h e m f rom 
enjoy ing w idespread use. A min imal 
number of artit icial corneas are 
be ing implanted each year, wh ich is 
tar below the potent ial d e m a n d , said 
Tr inkaus-Randal l . 
The invest igator and her asso-
ciates, however, are seek ing to 
develop a radically di f ferent t ype of 
arti t icial co rnea that may overcome 
the extrusion prob lem. The pros-
thes is wil l compr ise a central t rans-
parent d isc (hydrogel polymer) and a 
sur round ing porous skirt (b lown 
microt iber) : The implant wou ld 
replace the detect ive part of the 
native co rnea and wou ld be covered 
by an Intact epithel ial layer that is 
cont iguous to the sur rounding epi -
the l ium. It also wou ld al low tor "hea l -
i ng , " whereby stromal keratocytes 
migrate into the sur rounding skirt 
mater ia l , prol i ferate and synthes ize 
basement membrane components . 
"We need a type of mater ial that is 
porous enough so that cells f rom the 
s t roma, wh ich compr ises the main 
th ickness of the co rnea , can pen-
etrate it," the researcher exp la ined. 
"The resul t ing bond be tween the 
co rnea and the prosthesis wou ld 
b lock the d o w n w a r d growth of ep i th-
elial, or outer-layer, corneal cells, 
and thus prevent ext rus ion." 
The B U S M research t e a m , work-
ing wi th mater ia ls deve loped by 
po lymer chemis ts at the 3 M C o m -
pany in Minneso ta , a l ready has 
so lved many of the prob lems 
involved in des ign ing such a sys tem. 
Th is meant developing an artit icial 
mater ia l that wou ld be hospitable to 
the new cells and capable of surgical 
manipulat ion. In addi t ion, said 
Tr inkaus-Randal l , the mater ial had to 
be capab le of hold ing a sprayed-on 
layer of the key proteins involved in 
corneal g rowth , a process cal led 
laminat ion. "We had some mater ials 
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that main ta ined cell growth very 
we l l , " she said, "but we re jected 
t h e m b e c a u s e we couldn' t laminate 
the prote ins on t h e m . " 
Creat ing a prosthesis that provides 
a rel iable rep lacement for d a m a g e d 
corneas is a formidable chal lenge. 
Accord ing to the B U S M invest igator, 
the f irst prob lem that she and her 
assoc ia tes had to solve was creat ing 
an et tect ive cul ture sys tem tor grow-
ing new corneal epithel ial cel ls. The 
mater ia l that eventual ly proved most 
et tect ive was a polyvinyl a lcohol 
copo lymer hydrogel , deve loped at 
3 M . The invest igators found that 
d isks of the mater ia l , wh ich look and 
feel s imi lar to soft contact lenses, 
prov ide an excellent bed tor the 
growth and main tenance of epithel ial 
cel ls. 
Besides ident i fy ing a suitable 
mater ia l , however, the researchers 
also had to def ine the best condi -
t ions tor cul tur ing cells on the hydro-
gels prior to implantat ion. Param-
eters that were tes ted inc luded sur-
face type , length of cul ture t ime and 
number of cells added to the central 
por t ion. It also was necessary tor the 
researchers to mainta in a ba lance 
be tween growth and s lough ing . 
"As the cells grow and div ide, 
some of t h e m wil l s lough of t , " 
Transmission electron micrograph of corneal 
epithielial cells on tfie hiydrogel after eigfit days 
of culture. Several layers of epitfielium are pre-
sent and cell junctions can be detected. (Photo 
courtesy of Vickery E. Trinkaus-Randall, Ph.D.) 
expla ined the invest igator. "It you don' t 
mainta in a rough balance be tween the 
ones that are g rowing and those that 
are s lough ing oft whi le you ' re cul tur ing 
the cel ls, you get hyperprol i ferat ion of 
the cells and an errat ic epithel ial struc-
tu re . " 
The techn ique dev ised by the B U S M 
group, wh ich involves star t ing wi th a 
single layer of epithel ial cells and cu l -
tur ing t h e m for tour to f ive days, has 
p roduced excellent results in laboratory 
tests. Once the disk wi th cu l tu red cells 
is implanted, said Tr inkaus-Randal l , the 
cells cont inue to div ide. The host need 
not be the source of the cu l tured cells, 
she noted. 
"We've found that the epithel ial cells 
we ' re implant ing grow out beyond the 
disk onto host t issue, and the host 
epithel ial cells grow onto the disk, they 
don' t s e e m to be reject ing each other , " 
she sa id . 
Meet ing the second of the research 
venture 's major goals , c reat ing t ight 
bonds be tween the prosthesis and the 
native cornea, requires mater ials wi th 
qual i t ies quite di f ferent f rom those that 
make the disk work, said the invest i-
gator. "What we ' re work ing on is a 
per ipheral skirt, wh ich wil l be a t tached 
around the outs ide of the disk," said 
Tr inkaus-Randal l . "Whi le the disk is 
quite dense , th is mater ial is what 's 
known as a b lown microt iber and it's 
ext remely porous . " The porosi ty per-
mits the influx of cells f rom the inner 
layer of the pat ient 's co rnea , she noted. 
The mater ia l that the researchers 
current ly are using is another polymer, 
a polybuty lene. Tr inkaus-Randal l said 
that exper iments show it al lows the 
penetrat ion of corneal keratocytes; not 
clear yet, however, is whether it meets 
another key prerequis i te. 
"The skirt must hold a suture, and 
the hole created by the needle m'ust 
seal once you remove the su ture , " said 
Alexandra Vadasz, M.D., a research fel-
low in the B U S M Depar tment of O p h -
tha lmology. "It it tears w h e n you try to 
put a sti tch through it, it's not go ing to 
work as a long-term prosthes is . " 
Despite these hurdles, the researchers 
bel ieve that the use of this un ique 
Vickery Trinkaus-Randall, Ph.D., and her col-
legues seek to develop a radically different 
type of artificial cornea. (Photo by Bradford F. 
Herzog) 
keratoprosthesls Is promis ing. 
Other B U S M facul ty involved in 
the research include Howard 
Leibowitz, M.D., professor and chair-
man of the Depar tment of O p h -
tha lmology, and Carl Franzblau, 
Ph.D. , professor and cha i rman of the 
Depar tment of Biochemistry . 
"Richard P. Anthony 
S u g g e s t e d F u r t h e r R e a d i n g s 
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Cholesterol... 
continued from page 1 
b lood p lasma to the cells and back 
to the p lasma is accompl ished by 
the act ion of such proteins as apo-
l ipoprotein B, apol ipoprote in E and 
apol ipoprote in A - 1 . Zann is and his 
team found that a p o B fo rms a c o m -
plex wi th cholesterol and other lipids 
in the b loods t ream. This complex is 
known as low densi ty l ipoprotein 
(LDL) or " b a d " cholestero l . Accord -
ing to the researchers , LDL contains 
a s ingle a p o B molecule and 2,000 
cholesterol molecu les. High densi ty 
l ipoprote in (HDL) or " g o o d " choles-
terol , another type of lipid protein 
complex, is involved in the removal 
of cholesterol f rom the cells. (Please 
refer to diagram, page 6.) 
A p o B terr ies the cholesterol to the 
sur face of cells where it b inds to 
another prote in, cal led the LDL 
receptor . " In this regard, apoB 
serves as the key and the LDL 
receptor serves as the lock," 
exp la ined Zann is . Fol lowing b inding, 
LDL is taken into the cell where 
a p o B is dest royed and the choles-
terol is re leased to be ut i l ized by the 
cell as requ i red. 
Wha t concerns Zann is and his 
g roup is what happens w h e n the 
a p o B - L D L receptor system breaks 
d o w n , caus ing a harmful increase in 
b lood cholestero l . "The bui ldup of 
cholesterol may occur as a result of 
genet ic changes in one or the other 
p ro te in , " sa id Zann is . "The inter-
act ion or ' locking in ' of apoB and the 
LDL receptor is ineff icient and the 
cholestero l , rather than be ing deliv-
e red to the cell , bui lds up in the 
b loods t ream. " This increase in cho-
lesterol c logs the ar ter ies and 
increases the risk of a therosc leros is 
and heart d isease. 
Once the molecular s t ructure of 
a p o B was Identi f ied, the researchers 
ted the informat ion to a computer , 
wh ich ident i f ied the probable regions 
of a p o B involved in b inding to the 
LDL receptor. "The regions we iden-
t i f ied by computer still have to be 
ver i f ied by laboratory exper iments , but 
we th ink that a number of peop le wi th 
high levels of cholesterol in their b lood 
may have had changes in that part of 
the a p o B prote in. Now that we know 
the normal s t ructure of the prote in, we 
know what to look for," said Zann is . 
Computer analysis of the apoB pro-
tein was per fo rmed by David Atk inson, 
Ph.D. , a B U S M associate research pro-
fessor of medic ine and b iochemist ry . 
This analysis revealed several possible 
regions that may have to do wi th rec-
ogni t ion of receptor si tes. One region in 
part icular has a much higher posit ive 
charge than the rest of the molecule 
and is su r rounded by regions that also 
exhibit a posit ive charge, a l though to a 
lesser degree . 
"It is possible that several regions of 
a p o B must be together tor the molecule 
A BUSM research team headed hy Vassilis Zan-
nis, Ph.D., right, and Christos Cladaras, Ph.D., 
principal collahorator in the research, unraveled 
the genetic code of the protein molecule apo-
lipoprotein B (apoB) that transports cholesterol in 
the hloodstream. The team used recomhinant 
DNA techniques and computer analyses to 
sequence the 4,560 amino acids that make up 
apoB. (Photo hy Bradford F. Herzog) 
to be recogn ized by the LDL recep-
tor ," Zann is hypothes ized . "So far, it 
has been found that it you destroy 
the posit ive region of a p o B it wil l not 
be recogn ized by the LDL receptor . " 
Zann is said that this new under-
s tanding about the structure of a p o B 
wil l enable physic ians to sc reen 
patients w i th high cholesterol tor 
changes in the a p o B gene and a p o B 
prote in. Early identi t ication of this 
problem and proper t reatment wi th 
d rugs or dietary p rograms may pre-
vent or delay the development of 
heart d isease and extend the lite of 
these pat ients. 
Even more important , however, 
wil l be the abil i ty to identity mo lecu-
lar markers in suspec ted carr iers of 
th is mutat ion, tor instance, in people 
w i th a fami ly history of elevated 
blood-cholesterol levels, and to 
sc reen them as early as bir th or one 
year. 
"It you f ind markers that indicate 
th is individual wil l have high b lood 
cholesterol , then you can start pre-
vent ive measures right away, before 
any d a m a g e is done. It b lood tests 
of an adult male, tor example , show 
a level of cholesterol above 300, 
then the d a m a g e al ready has been 
done to the b lood vessels and all 
you can hope to do is to m in im ize 
the e f fec ts , " said Zann is . 
Zann is and his group also wil l be 
look ing at new ways to control the 
product ion of a p o B in the body . "It 
there are high levels of LDL in the 
b loods t ream, there also must be 
high levels of a p o B b e c a u s e a p o B is 
an essent ia l part of LDL. Our idea is 
that it one has lower levels of apoB 
avai lable, there may be less of an 
accumulat ion of LDL in the b lood 
and the body wil l f ind other ways of 
e l iminat ing the excess cholestero l , " 
exp la ined the researcher . 
The researchers have been able 
to start synthes iz ing apoB in vitro 
using the blueprint of the gene and 
can now start exper iment ing wi th 
d rugs that interrupt or s low down its 
product ion. 
"The hope is that it we understand 
Research in Progress u°sposla°e 
Boston University School of Medic ine PA\D 
Office of Informat ional Services Boston, Mass . 
f ?,Tn°c'j'.f^- Permit No. 53312 Boston, MA 02118 
C H R I S T O P H E R , I R E N E 
M E D L I B R A R Y 
8 0 E . C O N C O R O S T L 1 2 MEOOO 
the st ructure and act ion of all the pro-
teins involved in cholesterol t ranspor t 
and the regulat ion of their synthesis , 
then we' l l be in a posi t ion to descr ibe 
at the level of s imple molecu les all the 
d iseases that cause high cholesterol in 








I HDL receptor © © CELL 
I LDL receptor 
Schematic representation shows cholesterol 
heing transported in and out of a cell. 'B' repre-
sents LDL, a complex made up of lipids and 
apoB. 'E' represents apoE containing lipopro-
teins. 'A-1' represents HDL or apoA-1 containing 
lipoproteins. 'B' and 'E' deliver cholesterol to the 
cells and 'A-1' removes cholesterol from the cells. 
Breakdown of this process may cause the accu-
mulation of cholesterol in the hloodstream and 
result in clogged arteries. (Illustration hy Educa-
tional f^edia, BUSh/f) 
to d iagnose the condit ion and start 
t reatment before it's too late." 
Other members of the B U S M team 
that d e c o d e d the a p o B st ructure in 
record t ime inc lude: Chr is tos 
Cladaras, Ph.D. , a research instruc-
tor in medic ine and pr incipal co l -
laborator in the research ; Margar i ta 
Hadzopou lou-C ladaras , Ph.D. , a 
research fel low in the Sect ion of 
Molecular Genet ics ; Robert T. Nol te, 
a graduate student in B U S M ' s Bio-
physics Inst i tute; and Rafael Avi la, 
M.D., a co l league f rom the Harvard 
School of Public Heal th . 
Funds tor the research were pro-
v ided by the to l lowing organizat ions; 
the Nat ional Heart, Lung, and B lood 
Insti tute, the Nat ional Sc ience Foun-
dat ion, the Amer ican Heart Assoc ia -
t ion and the March of D imes Birth 
Detects Foundat ion. The H o o d Foun-
dat ion and the Medica l Foundat ion of 
Boston prov ided early suppor t tor 
the study. 
--Caroline H. Lupfer 
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